Life Sciences
Exscientia selects Milton Park for new laboratories
The expansion will see the firm occupy 20,151sq ft of laboratory and office space at 155 Brook Drive, which is part of the Science Vale Enterprise Zone.
Exscientia expands headquarters at The Oxford Science Park
The company, which initially occupied c7,800 sq ft in the Schrödinger Building is increasing capacity for its technology teams by expanding to 21,000 sq ft of facilities.
Orbit Discovery raises $7.6m to accelerate growth in peptide discovery business
The financing was led by Oxford Sciences Innovation, with participation from Borealis Ventures, Perivoli Innovations, and other institutional and individual investors.
Oxford-based Circassia reports revenue growth of 27%
The medical device company focused on point of care asthma diagnosis and management released a trading update for the six months ended 30 June 2021.
High Sheriff of Oxfordshire opens new R&D labs at Wood Centre for Innovation
The class II labs answer the significant demand from science and tech start-ups and SMEs for lab space in Oxford’s world-leading life sciences cluster in Headington.
Medical devices company Owen Mumford achieves B Corp certification
The Woodstock based company was awarded B Corp certification after demonstrating strict compliance to the rigorous requirements of this globally-recognised mark.
Oxford biotech firm plans clinical trial for next-generation COVID-19 vaccine
The studies will allow the company to assess the ability of its next-generation vaccine to boost the immune response against current and potential future strains of COVID-19.
ATDBio establishes molecular diagnostics lab at The Oxford Science Park
The 745 sq ft molecular diagnostics research and quality control lab will support its customers in developing improved molecular diagnostics for COVID-19 and other pathogens.
Exscientia acquires personalised medicine AI pioneer Allcyte
The combination expands Exscientia’s capabilities by enabling high content evaluation of individual patient biology in primary tumour tissues rather than artificial cell lines or animal models.
DJS Antibodies moves to newly converted lab space at Wood Centre for Innovation
Biotech start-up, DJS Antibodies, is the second company to move into the newly converted class II laboratory space at The Oxford Trust’s Wood Centre for Innovation.
G7 health summit highlights Oxfordshire’s thriving life sciences sector
The arrival of G7 health ministers to Oxford on Thursday 03 June will shine a spotlight on Oxfordshire’s considerable achievements in the life sciences sector.
Revenue quadruples in Sensyne Health trading update for 2021
The company has reported robust financial performance in its 2021 unaudited revenues of at least £9.0 million compared to £2.1 million in the 2020 audited accounts.